EYPT / EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success

EyePoint reported top-line data on two phase 2 trials for its lead pipeline candidate. The company focuses on serious eye disorders. more_horizontal

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing an more_horizontal

EyePoint Pharmaceuticals is developing the EYP-1901 treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy. Q2 more_horizontal

WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializi more_horizontal

EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial produc more_horizontal

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financ more_horizontal

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate re more_horizontal

Shares have lost 15% year to date. Durasert technology has been extensively validated and administered to over 80,000 patient eyes. more_horizontal